CJC-1295 without DAC (Mod GRF 1-29) is a modified 29-amino acid analog of growth hormone-releasing hormone (GHRH) that retains the short half-life characteristic of natural GHRH. Unlike the DAC-modified form, which extends half-life via albumin binding, the No DAC version is studied in research contexts where mimicking the natural pulsatile GH secretion pattern is important. This 5mg lyophilized format is suited for smaller research protocols and initial dosing studies.

Preclinical and in vitro research has investigated CJC-1295 (No DAC)’s high affinity for the GHRH receptor on pituitary somatotrophs, leading to downstream increases in growth hormone (GH) secretion. Studies have characterized its pharmacokinetic profile, noting rapid clearance that mirrors endogenous GHRH kinetics. The compound is frequently used in research examining GH pulse amplitude and frequency, and has been studied in combination with ghrelin receptor agonists such as Ipamorelin to examine additive secretagogue effects on GH release.

CJC-1295 (No DAC) is a standard reference compound in growth hormone axis research, GHRH receptor pharmacology, and pituitary function studies. Its well-characterized binding profile and predictable pharmacokinetics make it a reliable tool for researchers studying GHRH analog activity.

Disclaimer: This product is intended for in vitro research and laboratory use only. It is not intended for human or veterinary use, consumption, or injection. Not approved by the FDA. Not intended to diagnose, treat, cure, or prevent any disease or medical condition. For use by qualified researchers only.